
Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Reduce Size, Reduce Disease" Campaign
BANGKOK, July 8, 2025 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions provider in Asia, is organizing the "Obesity is a Disease" seminar as part of its "Reduce Size, Reduce Disease" awareness campaign. The seminar aims to reinforce the message that obesity is more than a cosmetic concern, and solutions to manage the disease among healthcare practitioners. It is a silent national public health crisis that significantly impacts individuals living with obesity, particularly women.
Studies have highlighted the urgency of addressing rising obesity rates, as the 2014 National Health Examination Survey found that 37.5% of Thais aged 15 and over were obese (BMI > 25), with the rate for women at 41.8%. By 2023, this figure had climbed to 45% for women, compared to 38% for men 1. Women with obesity face an increased risk of serious health conditions, including Polycystic Ovary Syndrome (PCOS), uterine problems, infertility, breast and endometrial cancer. The "Reduce Size, Reduce Disease" campaign therefore aims not only to encourage behavioral change but also to dismantle the social stigma that treats obesity as a personal failure, fostering an understanding of it as a chronic disease that requires proper care.
Ms. Sunaiyanaa Kidkasetpaisal, Zuellig Pharma's General Manager for Commercialization in Thailand, said, "Zuellig Pharma is dedicated to enhancing the health of the Thai people by championing the understanding that obesity is not about aesthetics, and instead is a chronic disease requiring holistic treatment. We believe that equitable access to healthcare is the foundation of a sustainable society, and our 'Reduce Size, Reduce Disease' campaign is a direct reflection of this commitment, moving beyond promoting new treatment innovations to providing comprehensive knowledge and practical guidance on weight management. This seminar reflects our dedication in driving change and shifting the societal narrative on obesity from judgment to understanding and care, for the long-term health for everyone."
The "Obesity is a Disease" seminar involved healthcare practitioners from all over Thailand, who are committed to educating and deepening their understanding of obesity as a disease among Thais; and constantly find ways and solutions to help fight the disease.
Prof. Dr. Rungsima Wanitphakdeedecha, Head of the Department of Dermatology, Chief of the Division of Dermatologic Surgery, and Director of the Siriraj Skin Laser Center at the Faculty of Medicine Siriraj Hospital, Mahidol University, explained, "At its heart, the "Reduce Size, Reduce Disease" campaign is about inspiring people in Thailand to embrace a holistic approach to their well-being, focusing on safe and effective health management to prevent comorbidities linked to obesity. It shows that when we truly invest in our own well-being, long-term health will be sustainable."
Asst. Prof. Dr. Mart Maiprasert, Dean and Chairman of the Graduate Program Executive Committee at the College of Integrative Medicine (CIM), said "Effective weight management today hinges on multiple factors, including a strong partnership between patients and medical experts, proper lifestyle habits, good nutrition, and consistent exercise. Together, these elements form the foundation of what we call the 'X2' approach, which emphasizes that being healthy is not achieved through dieting or exercise alone but through a sustainable, balanced integration of both for lasting results."
Master Dr. Rassapoom Sumaetheiwit, a specialist in dermatology and aesthetic medicine, added, "Helping our clients with effective body composition management is not just a series of procedures, but an art grounded in medical science, demanding a deep, individual understanding of each patient to tailor the most appropriate and safe treatment plan. This integrated approach ensures that losing weight is not merely about aesthetics, but about achieving genuine health and physical balance. Our commitment is to provide this level of comprehensive, personalized care to deliver safe and sustainable long-term results."
The "Reduce Size, Reduce Disease" project aims to raise awareness that "Obesity is a disease" requiring medical attention, while also spotlighting the urgent public health challenge that obesity represents in Thailand.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Korea Herald
a day ago
- Korea Herald
Scale Hits New High: HNC 2025 Concludes with Resounding Success, Driving a New Wave of Health Industry Upgrades
SHANGHAI, July 18, 2025 /PRNewswire/ -- Jointly organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products and Sinoexpo Informa Markets, the "Healthplex Expo 2025, Natural & Nutraceutical Products China 2025" (HNC 2025) was successfully held from June 24 to 26 at the National Exhibition and Convention Center (Shanghai). The HNC 2025 once again achieved a historic breakthrough in scale, winning high praise from all participants. Held concurrently with Hi & Fi Asia-China, ProPak China & FoodPack China, and Starch Expo, the HNC built a business platform integrating the entire industry chain from upstream ingredient supply to end-product distribution. The total exhibition area exceeded 200,000 sqm, bringing together more than 2,500 exhibitors from around the world. Meanwhile, 93,080 professional buyers from 137 countries and regions attended the shows for business exchange and negotiation — a year-on-year increase of 21.2% — fully showcasing the latest achievements and future directions of the health industry, and highlighting its tremendous vitality and boundless potential. The HNC deeply aggregates global resources and builds an industry ecosystem for collaborative development. This year's HNC not only gathered leading enterprises from across China but also attracted industry leaders from more than 30 countries and regions, including Australia, New Zealand, Italy, South Korea, Japan, Malaysia, the United States, Canada, Singapore, Spain, Norway, etc. National pavilions and exhibitors from Italy, Spain, Slovenia, the United States, and Japan made their debuts in China at the exhibition. Local delegations from across China also demonstrated their regional strengths — for example, Jilin pavilion featured its renowned ginseng and antler products, while Xizang pavilion presented its unique highland resources and premium wellness treasures. Both domestic and international exhibitors displayed a diverse range of products and solutions spanning nutritional and health supplements, imported dietary supplements, traditional tonic foods, health foods and beverages, anti-aging beauty products, emotional healing solutions, weight management products, healthcare devices and equipment, as well as third-party professional services. As a vital platform for information exchange, product launches, technology discussions, and market expansion in the health industry, HNC continues to attract a growing number of domestic and international companies, driving deeper collaboration and development across the global health and nutrition sector. Staying true to the innovative spirit of HNC, the exhibition spotlighted trending topics such as sports nutrition, aromatherapy, health foods and beverages, and the medicine and food homology, and curated several themed zones. Highlights included the brand-new "Hi Energy Camp", "Healing Workshop", "Light Wellness Awakening • Food & Beverage Festival", as well as the fully upgraded "TCM Nutrition Zone." These zones combined product showcases, competitions, and immersive experiences, while also collaborating for the first time with Douyin E-Commerce, the leading interest-based e-commerce platform, to offer brands live-streaming sales channels. This cross-ecosystem partnership empowered multiple brands to drive GMV growth and create best-selling products, putting innovative practice into action to boost domestic health consumption and reshape the health ecosystem through category evolution. All activities received enthusiastic feedback from onsite participants. As an industry hub for insights and exchange, the HNC 2025 also hosted more than 50 high-caliber industry events, reaching a new high in scale. The agenda covered professional industry conferences and forums, new product launches, international brand exchanges, innovative interactive experiences, business matchmaking, etc. Hot topics included weight management, applications of medicine and food homology, probiotic research, regulations and market trends for foods for special medical purposes (FSMPs), development of low-GI and whole-grain products, brand building and marketing strategies, hit product incubation, cross-border e-commerce strategies, nutrition across the life cycle, etc. Major events included the 14th Nutraceutical Industry Development Conference (NIDC), The 19th Innovation Hub for Nutrition and Health Food, The 2nd Jilin's Changbai Mountain Ginseng Health (Shanghai) Forum & Related Industry Economic and Trade Matchmaking, 2025 Industry Forum on Medicine and Food Homology, NutriGlobal 2025: Private Advisory Forum for Supply Chain Innovation in China's Health Market, among others. These sessions, held in both Chinese and bilingual formats, gathered government officials, industry association leaders, research experts, and business executives, who shared forward-looking insights and engaged in in-depth exchanges with attendees onsite. Meanwhile, to enhance the efficiency and precision of connections between exhibitors and channel partners, the HNC meticulously organized five targeted business matchmaking sessions onsite. Well-known MCN agencies were specially invited, along with top e-commerce influencers and leading private-domain group leaders, to source new products. Major offline supermarket chains and pharmacy chains also actively participated in the matchmaking sessions. Through this kind of business matchmaking model, broader and more diversified market channels are opened up for exhibitors. To enrich the overall experience for visitors, the HNC significantly upgraded its "Discovery Tour" interactive activity, carefully planning three themed tour routes: Beauty & Anti-Aging, Weight Management, and Tonic Food. Visitors showed great enthusiasm by checking in at booths to learn about the latest products and solutions under each theme. In addition, the HNC launched an all-new immersive cultural experience project called "Trendy Herbal Shop", showcasing the integration of food-medicine homology traditions, as well as a limited-time "Seal-Collecting Tour" activity, which added vibrant fun and cultural depth to the exhibition. The HNC 2025 in Shanghai has come to a successful close. The organizers would like to extend our heartfelt thanks to all exhibitors, professional visitors, partners, and media friends for their invaluable support and enthusiastic participation. Looking ahead, the next stop for HNC will be the " Healthplex Expo, Natural & Nutraceutical Products Shenzhen 2025" (HNC Shenzhen 2025), taking place from December 16 to 18, 2025, at the Shenzhen World Exhibition & Convention Center. Next year at the "Healthplex Expo 2026, Natural & Nutraceutical Products China 2026" (HNC 2026) in Shanghai, we expect to see you again from June 15th to 17th, 2026. We look forward to reuniting with colleagues from the global health and nutrition industry to share the grand occasions, and to jointly write an even more brilliant new chapter for the health industry.

Korea Herald
2 days ago
- Korea Herald
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation
SEOUL, South Korea, July 18, 2025 /PRNewswire/ -- DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) system, for the treatment of atrial fibrillation (AF). The trial is designed to evaluate the safety and efficacy of laparoscopic RDN in patients with recurrent AF following pulmonary vein isolation (PVI) and resistant hypertension. It will be conducted as a multicenter, prospective, single-arm, open-label exploratory study. HyperQure™ is a next-generation laparoscopic RDN device developed over the past decade under the leadership of Professor Chang-Wook Jeong at Seoul National University Hospital. By adopting an extravascular approach, HyperQure™ addresses key limitations of conventional intravascular RDN, offering direct anatomical access to renal nerves with the potential for improved precision and outcomes. DeepQure is also conducting RDN clinical trials for resistant hypertension in both South Korea and the United States. Patient enrollment is nearing completion domestically, while trials are actively underway at five major academic medical centers across the U.S. The MFDS's approval for this new indication marks an important milestone, expanding HyperQure™'s potential from hypertension to atrial fibrillation and reinforcing its technical scalability and multi-disease therapeutic potential. HyperQure™ is ISO 13485–certified, GMP-compliant, and was designated as Innovative Medical Device No. 36 by the MFDS, underscoring its clinical relevance and breakthrough innovation. "This approval validates HyperQure™ as a next-generation solution that overcomes the limitations of traditional RDN techniques," said a DeepQure spokesperson. "With parallel trials in resistant hypertension and now atrial fibrillation, we are accelerating our push into the global cardiovascular market with a truly differentiated solution." About DeepQure DeepQure is a medical technology company pioneering minimally invasive therapies for cardiovascular and autonomic nervous system disorders. Founded by experts in clinical medicine, engineering, and global healthcare, the company is focused on developing breakthrough solutions that address unmet needs in cardiovascular diseases. DeepQure is headquartered in Seoul, South Korea, with clinical programs active in both Korea and the United States. About HyperQure™ RDN System HyperQure™ is DeepQure's proprietary laparoscopic renal denervation (RDN) system designed to treat conditions such as resistant hypertension and atrial fibrillation. Unlike conventional intravascular approaches, HyperQure™ utilizes an extravascular route to access and ablate renal nerves with enhanced precision. The system has been designated as an Innovative Medical Device by the Korean MFDS and has obtained ISO 13485 and GMP certifications, enabling global clinical deployment.

Korea Herald
2 days ago
- Korea Herald
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
SEONGNAM, South Korea, July 17, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. The candidate incorporates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu' to enhance protective efficacy. SK bioscience previously utilized adjuvants in its COVID-19 vaccine, 'SKYCovione', and now seeks to expand this technology to influenza vaccines as part of its broader platform strategy. NBP607B contains an adjuvant developed by the Vaccine Formulation Institute (VFI), a Swiss-based non-profit vaccine research organization. Comprising multiple immune-boosting components, the adjuvant is expected to induce strong immune responses and antibody production in elderly individuals. SK bioscience has proactively conducted non-clinical studies since 2023 and reported promising results. The Phase 1/2 clinical trial is scheduled to begin during the upcoming Northern Hemisphere flu season, enrolling approximately 320 older adults in Korea and abroad. The study will evaluate the vaccine's immunogenicity and safety compared to an approved high-immunogenicity flu vaccine, with interim results expected by 2027. This marks the first attempt by a Korean company to submit an IND to develop a high-immunogenicity influenza vaccine using an adjuvant. If successful, the company plans to leverage the platform for other vaccines and establish a competitive edge in the global high-value vaccine market. The development aligns with global health authorities' increasing recommendations for enhanced flu vaccines in high-risk groups. The U.S. Centers for Disease Control and Prevention (CDC)'s Advisory Committee on Immunization Practices (ACIP) recommends high-dose or adjuvanted influenza vaccines for adults aged 65 and older. The World Health Organization (WHO) also supports the use of adjuvanted vaccines for vulnerable populations. In Korea, the Korea Disease Control and Prevention Agency (KDCA) has indicated that domestically developed high-immunogenicity vaccines may be considered for inclusion in the National Immunization Program (NIP) if they meet appropriate criteria. According to market research firm Mordor Intelligence, the global vaccine market is projected to grow from USD 83.9 billion in 2025 to USD 114.8 billion in 2030, with an average annual growth rate of 6.5%. Demand for high-immunogenicity vaccines is expected to rise continuously due to global aging and the increasing number of immunocompromised individuals and those with chronic illnesses. SKYCellflu, SK bioscience's existing cell-based influenza vaccine, has already been recognized for its innovation. It became the world's first cell-based flu vaccine to receive prequalification (PQ) from the WHO and is currently approved in 11 countries, with supply through international procurement programs by United Nations Children's Fund (UNICEF) and Pan American Health Organization (PAHO). Jaeyong Ahn, CEO of SK bioscience, said, "We believe the combination of our proven SKYCellflu platform and our experience in adjuvanted vaccine development positions us well for success. We aim to establish a differentiated presence in the high-immunogenicity vaccine market while building a flexible platform for future infectious disease preparedness."